Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimers DiseaseReport as inadecuate




Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimers Disease - Download this document for free, or read online. Document in PDF available to download.

International Journal of Alzheimer-s DiseaseVolume 2012 2012, Article ID 628070, 14 pages

Review Article

Department of Clinical Sciences, Pfizer Inc., Collegeville, PA 19426, USA

Janssen Alzheimer Immunotherapy Research & Development, LLC., South San Francisco, CA 94080, USA

Received 1 August 2011; Accepted 21 September 2011

Academic Editor: Marwan Sabbagh

Copyright © 2012 Kasia Lobello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

As the societal and economic burdens of Alzheimer-s disease AD continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the development of various immunotherapeutic approaches targeting beta amyloid. This paper reviews active and passive approaches aimed at beta amyloid, with a focus on clinical trial data.





Author: Kasia Lobello, J. Michael Ryan, Enchi Liu, Gregory Rippon, and Ronald Black

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents